RecruitingPhase 4NCT06213324

Neural Circuit Effects of Ketamine in Depression

Neural Circuit-Specific Mechanisms of Ketamine's Effect on Anhedonia and Anxiety in Depression Using Ultra-High Field 7-Tesla MRI


Sponsor

Icahn School of Medicine at Mount Sinai

Enrollment

120 participants

Start Date

Jan 31, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This project is designed to examine the role of the subgenual anterior cingulate cortex (sgACC) in anhedonia and anxiety in humans with depression, as well as the acute and sustained effects of ketamine on agACC activation and depression symptoms.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is researching how ketamine — a medication being explored for treatment-resistant depression — affects brain circuits involved in mood. Researchers will use brain scans and other measurements to better understand why ketamine works for some people with depression, which could help develop better treatments in the future. Healthy volunteers are also being recruited for comparison. **You may be eligible if...** - You are 18 to 65 years old - You have been diagnosed with major depressive disorder (MDD) currently at moderate or greater severity (patient group) - OR you are a healthy volunteer without depression (comparison group) - You are able to give informed consent and follow study requirements - Women of childbearing age must use reliable contraception and have a negative pregnancy test **You may NOT be eligible if...** - You have a history of schizophrenia, bipolar disorder, psychosis, or a neurodevelopmental disorder - You have active suicidal thoughts or a recent history of suicide attempts - You have a history of ketamine, PCP, or other dissociative drug misuse - You have significant heart, liver, or kidney problems - You are currently pregnant or breastfeeding - You have a substance use disorder (other than mild alcohol or cannabis use) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGKetamine

0.5 mg/kg ketamine dissolved in 100 mL saline, delivered intravenously

DRUGPlacebo

Normal saline delivered intravenously


Locations(1)

Icahn School of Medicine at Mount Sinai

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06213324


Related Trials